title: Effect of positive bone marrow EBV in situ hybridization in staging and survival of localized extranodal natural killer/T-cell lymphoma, nasal-type.
abstract: OBJECTIVE
  The aim of the study was to determine the effect of EBV-encoded RNA-1 in situ hybridization (EBER-1 ISH) in bone marrow specimens on survival outcome in patients with clinical stage I/II natural killer/T-cell lymphoma.
  
  
  METHODS
  We systematically did EBER-1 ISH on 182 archival bone marrow tissues from 91 patients who were diagnosed of stage I/II natural killer/T-cell lymphoma and analyzed the correlation between bone marrow EBER-1 ISH status and survival. We defined minimal bone marrow involvement and definite bone marrow involvement to distinguish the subgroups who revealed EBV-positive cells from normal marrow by EBER-1 ISH from those who showed typical neoplastic cells in bone marrow biopsies.
  
  
  RESULTS
  In total, 17 of the 91 (18.7%) patients showed positivity for EBER-1 ISH at least in one of the bilateral bone marrow biopsies with 14 minimal bone marrow involvements and 3 definite bone marrow involvements. Patients with positive bone marrow EBER-1 ISH showed significantly poorer overall survival than those who were negative for bone marrow EBER-1 ISH (median survival, 16.1 months versus not reached; P = 0.045).
  
  
  CONCLUSIONS
  Considering a high proportion of stage I/II patients (15.4%) with minimal in bone marrow specimens, bone marrow EBER-1 ISH should be routinely done in all patients with localized disease for more accurate staging.
authors.affiliation: Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
authors.forename: Jeeyun
authors.initials: J
authors.lastname: Lee
authors.forename: Cheolwon
authors.initials: C
authors.lastname: Suh
authors.forename: Jooryung
authors.initials: J
authors.lastname: Huh
authors.forename: Hyun Jung
authors.initials: HJ
authors.lastname: Jun
authors.forename: Kihyun
authors.initials: K
authors.lastname: Kim
authors.forename: Chulwon
authors.initials: C
authors.lastname: Jung
authors.forename: Keunchil
authors.initials: K
authors.lastname: Park
authors.forename: Yeon Hee
authors.initials: YH
authors.lastname: Park
authors.forename: Young Hyeh
authors.initials: YH
authors.lastname: Ko
authors.forename: Won Seog
authors.initials: WS
authors.lastname: Kim
mesh_terms: D000368:Aged; D001853:Bone Marrow / Q000821:virology*; D001854:Bone Marrow Cells / Q000378:metabolism; D017252:CD3 Complex / Q000096:biosynthesis; D020031:Epstein-Barr Virus Infections / Q000150:complications*; D005260:Female; D004854:Herpesvirus 4, Human / Q000378:metabolism*; D006801:Humans; D017403:In Situ Hybridization; D007694:Killer Cells, Natural / Q000378:metabolism / Q000821:virology; D016399:Lymphoma, T-Cell / Q000401:mortality* / Q000821:virology*; D008297:Male; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000401:mortality* / Q000821:virology*; D009367:Neoplasm Staging / Q000379:methods*
chemical_list: D017252:CD3 Complex